Modeling the role of IL-2 in the interplay between CD4+ helper and regulatory T cells: Assessing general dynamical properties

Journal of Theoretical Biology

Volumn 262, Issue 4, 2010, Pages 720-732

  García Martínez, Karina ^a   León, Kalet ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Interleukin 2 and T cells dynamics; Mathematical model

Indexed keywords

INTERLEUKIN 2;

ANTIGEN; ASSESSMENT METHOD; CELL ORGANELLE; IMMUNE SYSTEM; INHIBITION; NUMERICAL MODEL; TOLERANCE;

ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE PRODUCTION; HELPER CELL; IMMUNE RESPONSE; IMMUNITY; LIFE CYCLE; LYMPH NODE; MATHEMATICAL MODEL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; STEADY STATE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGEN PRESENTATION; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; COMPUTER SIMULATION; HUMANS; IMMUNE SYSTEM; INTERLEUKIN-2; KINETICS; LYMPH NODES; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 77649337932     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2009.10.025     Document Type: Article

References (60)

1. Ahmadzadeh M., Rosenberg S.A. IL-2 administration increases CD4+CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006, 107(6):2409-2414.
2. Almeida A.R., et al. Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. J. Immunol. 2002, 169(9):4850-4860.
3. Almeida A.R., Zaragoza B., Freitas A.A. Indexation as a novel mechanism of lymphocyte homeostasis: the number of CD4+CD25+ regulatory T cells is indexed to the number of IL-2-producing cells. J. Immunol. 2006, 177(1):192-200.
4. Barthlott T., et al. CD25+ CD4+ T cells compete with naive CD4+ T cells for IL-2 and exploit it for the induction of IL-10 production. Int. Immunol. 2005, 17(3):279-288.
5. Blattman J.N., et al. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 2003, 9(5):540-547.
6. Borghans J.A., de Boer R.J., Segel L.A. Extending the quasi-steady state approximation by changing variables. Bull. Math. Biol. 1996, 58(1):43-63.
7. Carneiro J., et al. When three is not a crowd: a crossregulation model of the dynamics and repertoire selection of regulatory CD4+ T cells. Immunol. Rev. 2007, 216:48-68.
8. Cederbom L., Hall H., Ivars F. CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur. J. Immunol. 2000, 30(6):1538-1543.
9. Cesana G.C., et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J. Clin. Oncol. 2006, 24(7):1169-1177.
10. Church A.C. Clinical advances in therapies targeting the interleukin-2 receptor. QJM 2003, 96(2):91-102.
11. de la Rosa M., et al. Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur. J. Immunol. 2004, 34(9):2480-2488.
12. Duprez V., Dautry-Varsat A. Receptor-mediated endocytosis of interleukin 2 in a human tumor T cell line. Degradation of interleukin 2 and evidence for the absence of recycling of interleukin receptors. J. Biol. Chem. 1986, 261(33):15450-15454.
13. Fallon E.M., et al. Increased endosomal sorting of ligand to recycling enhances potency of an interleukin-2 analog. J. Biol. Chem. 2000, 275(10):6790-6797.
14. Fallon E.M., Lauffenburger D.A. Computational model for effects of ligand/receptor binding properties on interleukin-2 trafficking dynamics and T cell proliferation response. Biotechnol. Prog. 2000, 16(5):905-916.
15. Fishman M., et al. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J. Immunother 2008, 31(1):72-80.
16. Frasca L., et al. Anergic T cells effect linked suppression. Eur. J. Immunol. 1997, 27(12):3191-3197.
17. Grossman Z. Recognition of self and regulation of specificity at the level of cell populations. Immunol. Rev. 1984, 79:119-138.
18. Grossman Z., Paul W.E. Self-tolerance: context dependent tuning of T cell antigen recognition. Semin. Immunol. 2000, 12(3):197-203.
19. Hemar A., et al. Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor alpha, beta, and gamma chains. J. Cell Biol. 1995, 129(1):55-64.
20. Horak I. Immunodeficiency in IL-2-knockout mice. Clin. Immunol. Immunopathol. 1995, 76(3 Pt 2):S172-S173.
21. Jelley-Gibbs D.M., et al. Two distinct stages in the transition from naive CD4 T cells to effectors, early antigen-dependent and late cytokine-driven expansion and differentiation. J. Immunol. 2000, 165(9):5017-5026.
22. Kamimura D., et al. IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb. J. Immunol. 2006, 177(1):306-314.
23. King C., et al. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004, 117(2):265-277.
24. Kudo-Saito C., et al. Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity. Cancer Immunol. Immunother 2007, 56(12):1897-1910.
25. Kuniyasu Y., et al. Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int. Immunol. 2000, 12(8):1145-1155.
26. Leon K., et al. Modelling T-cell-mediated suppression dependent on interactions in multicellular conjugates. J. Theor. Biol. 2000, 207(2):231-254.
27. Leon K., et al. How regulatory CD25(+)CD4(+) T cells impinge on tumor immunobiology? On the existence of two alternative dynamical classes of tumors. J. Theor. Biol. 2007, 247(1):122-137.
28. Leon K., Faro J., Carneiro J. A general mathematical framework to model generation structure in a population of asynchronously dividing cells. J. Theor. Biol. 2004, 229(4):455-476.
29. Lin C.T., et al. DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity. Immunol. Lett. 2007, 114(2):86-93.
30. Lodolce J.P., et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998, 9(5):669-676.
31. Lombardi G., et al. Anergic T cells as suppressor cells in vitro. Science 1994, 264(5165):1587-1589.
32. Malek T.R., et al. Broad programming by IL-2 receptor signaling for extended growth to multiple cytokines and functional maturation of antigen-activated T cells. J. Immunol. 2001, 166(3):1675-1683.
33. Malek T.R., et al. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 2002, 17(2):167-178.
34. Malek T.R., Bayer A.L. Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 2004, 4(9):665-674.
35. Miller M.J., et al. Imaging the single cell dynamics of CD4+ T cell activation by dendritic cells in lymph nodes. J. Exp. Med. 2004, 200(7):847-856.
36. Murali-Krishna K., et al. In vivo dynamics of anti-viral CD8 T cell responses to different epitopes. An evaluation of bystander activation in primary and secondary responses to viral infection. Adv. Exp. Med. Biol. 1998, 452:123-142.
37. Pandiyan P., et al. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat. Immunol. 2007, 8(12):1353-1362.
38. Papiernik M., et al. T cell deletion induced by chronic infection with mouse mammary tumor virus spares a CD25-positive, IL-10-producing T cell population with infectious capacity. J. Immunol. 1997, 158(10):4642-4653.
39. Peschon J.J., et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J. Exp. Med. 1994, 180(5):1955-1960.
40. Purton J.F., et al. Antiviral CD4+ memory T cells are IL-15 dependent. J. Exp. Med. 2007, 204(4):951-961.
41. Razi-Wolf Z., Hollander G.A., Reiser H. Activation of CD4+ T lymphocytes form interleukin 2-deficient mice by costimulatory B7 molecules. Proc. Natl. Acad. Sci. USA 1996, 93(7):2903-2908.
42. Read S., et al. CD38+ CD45RB(low) CD4+ T cells: a population of T cells with immune regulatory activities in vitro. Eur. J. Immunol. 1998, 28(11):3435-3447.
43. Sadlack B., et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993, 75(2):253-261.
44. Scheffold A., Huhn J., Hofer T. Regulation of CD4+CD25+ regulatory T cell activity: it takes (IL-)two to tango. Eur. J. Immunol. 2005, 35(5):1336-1341.
45. Schorle H., et al. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 1991, 352(6336):621-624.
46. Smith K.A. Interleukin-2: inception, impact, and implications. Science 1988, 240(4856):1169-1176.
47. Smith K.A. The quantal theory of how the immune system discriminates between "self and non-self". Med. Immunol. 2004, 3(1):3.
48. Smith K.A. Determining to divide: how do cells decide?. J. Biol. Phys. 2005, 31:261-272.
49. Smith K.A. The quantal theory of immunity. Cell Res. 2006, 16(1):11-19.
50. Suzuki H., et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 1995, 268(5216):1472-1476.
51. Taams L.S., et al. Anergic T cells actively suppress T cell responses via the antigen-presenting cell. Eur. J. Immunol. 1998, 28(9):2902-2912.
52. Takahashi T., et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 1998, 10(12):1969-1980.
53. Tang Q., et al. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat. Immunol. 2006, 7(1):83-92.
54. Thornton A.M., et al. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+T cell suppressor function. J. Immunol. 2004, 172(11):6519-6523.
55. Thornton A.M., Shevach E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 1998, 188(2):287-296.
56. Usherwood E.J., Crowther G., Woodland D.L. Apoptotic cells are generated at every division of in vitro cultured T cell lines. Cell Immunol. 1999, 196(2):131-137.
57. von Freeden-Jeffry U., et al. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J. Exp. Med. 1995, 181(4):1519-1526.
58. Van Parijs L., et al. Functional responses and apoptosis of CD25 (IL-2R alpha)-deficient T cells expressing a transgenic antigen receptor. J. Immunol. 1997, 158(8):3738-3745.
59. Willerford D.M., et al. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995, 3(4):521-530.
60. Wolf M., Schimpl A., Hunig T. Control of T cell hyperactivation in IL-2-deficient mice by CD4(+)CD25(-) and CD4(+)CD25(+) T cells: evidence for two distinct regulatory mechanisms. Eur. J. Immunol. 2001, 31(6):1637-1645.